Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.
Identifieur interne : 000870 ( Main/Exploration ); précédent : 000869; suivant : 000871Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.
Auteurs : Ching-Tsai Lin [Taïwan] ; Wen-Nan Huang [Taïwan] ; Chia-Wei Hsieh [Taïwan] ; Yi-Ming Chen [Taïwan] ; Der-Yuan Chen [Taïwan] ; Tsu-Yi Hsieh [Taïwan] ; Yi-Hsing Chen [Taïwan]Source :
- Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [ 1995-9133 ] ; 2019.
Descripteurs français
- KwdFr :
- Administration par voie intraveineuse, Adolescent, Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Antirhumatismaux (administration et posologie), Antirhumatismaux (effets indésirables), Enfant, Facteurs de risque, Facteurs temps, Femelle, Humains, Indice de gravité médicale, Jeune adulte, Mâle, Polyarthrite rhumatoïde (traitement médicamenteux), Résistance aux substances, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Taïwan.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Antirhumatismaux.
- effets indésirables : Anticorps monoclonaux humanisés, Antirhumatismaux.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- Administration par voie intraveineuse, Adolescent, Adulte, Adulte d'âge moyen, Enfant, Facteurs de risque, Facteurs temps, Femelle, Humains, Indice de gravité médicale, Jeune adulte, Mâle, Résistance aux substances, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Taïwan.
- Wicri :
- geographic : Taïwan.
English descriptors
- KwdEn :
- Administration, Intravenous, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Arthritis, Rheumatoid (drug therapy), Child, Drug Resistance, Female, Humans, Male, Middle Aged, Risk Factors, Severity of Illness Index, Taiwan, Time Factors, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- geographic : Taiwan.
- drug therapy : Arthritis, Rheumatoid.
- Administration, Intravenous, Adolescent, Adult, Aged, Aged, 80 and over, Child, Drug Resistance, Female, Humans, Male, Middle Aged, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Young Adult.
Abstract
To evaluate the long-term safety and effectiveness of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Taiwan.
DOI: 10.1016/j.jmii.2017.04.002
PubMed: 28734675
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A75
- to stream PubMed, to step Curation: 000A75
- to stream PubMed, to step Checkpoint: 000347
- to stream Ncbi, to step Merge: 001669
- to stream Ncbi, to step Curation: 001669
- to stream Ncbi, to step Checkpoint: 001669
- to stream Main, to step Merge: 000870
- to stream Main, to step Curation: 000870
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.</title><author><name sortKey="Lin, Ching Tsai" sort="Lin, Ching Tsai" uniqKey="Lin C" first="Ching-Tsai" last="Lin">Ching-Tsai Lin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Wen Nan" sort="Huang, Wen Nan" uniqKey="Huang W" first="Wen-Nan" last="Huang">Wen-Nan Huang</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Chia Wei" sort="Hsieh, Chia Wei" uniqKey="Hsieh C" first="Chia-Wei" last="Hsieh">Chia-Wei Hsieh</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Yi Ming" sort="Chen, Yi Ming" uniqKey="Chen Y" first="Yi-Ming" last="Chen">Yi-Ming Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Der Yuan" sort="Chen, Der Yuan" uniqKey="Chen D" first="Der-Yuan" last="Chen">Der-Yuan Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Ron Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Ron Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Tsu Yi" sort="Hsieh, Tsu Yi" uniqKey="Hsieh T" first="Tsu-Yi" last="Hsieh">Tsu-Yi Hsieh</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Yi Hsing" sort="Chen, Yi Hsing" uniqKey="Chen Y" first="Yi-Hsing" last="Chen">Yi-Hsing Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: ysanne@vghtc.gov.tw.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:28734675</idno><idno type="pmid">28734675</idno><idno type="doi">10.1016/j.jmii.2017.04.002</idno><idno type="wicri:Area/PubMed/Corpus">000A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A75</idno><idno type="wicri:Area/PubMed/Curation">000A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A75</idno><idno type="wicri:Area/PubMed/Checkpoint">000347</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000347</idno><idno type="wicri:Area/Ncbi/Merge">001669</idno><idno type="wicri:Area/Ncbi/Curation">001669</idno><idno type="wicri:Area/Ncbi/Checkpoint">001669</idno><idno type="wicri:Area/Main/Merge">000870</idno><idno type="wicri:Area/Main/Curation">000870</idno><idno type="wicri:Area/Main/Exploration">000870</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.</title><author><name sortKey="Lin, Ching Tsai" sort="Lin, Ching Tsai" uniqKey="Lin C" first="Ching-Tsai" last="Lin">Ching-Tsai Lin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Wen Nan" sort="Huang, Wen Nan" uniqKey="Huang W" first="Wen-Nan" last="Huang">Wen-Nan Huang</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Chia Wei" sort="Hsieh, Chia Wei" uniqKey="Hsieh C" first="Chia-Wei" last="Hsieh">Chia-Wei Hsieh</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Yi Ming" sort="Chen, Yi Ming" uniqKey="Chen Y" first="Yi-Ming" last="Chen">Yi-Ming Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Der Yuan" sort="Chen, Der Yuan" uniqKey="Chen D" first="Der-Yuan" last="Chen">Der-Yuan Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Ron Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biomedical Science and Ron Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Tsu Yi" sort="Hsieh, Tsu Yi" uniqKey="Hsieh T" first="Tsu-Yi" last="Hsieh">Tsu-Yi Hsieh</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung</wicri:regionArea><wicri:noRegion>Taichung</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Yi Hsing" sort="Chen, Yi Hsing" uniqKey="Chen Y" first="Yi-Hsing" last="Chen">Yi-Hsing Chen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: ysanne@vghtc.gov.tw.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</title><idno type="eISSN">1995-9133</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Child</term><term>Drug Resistance</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>Taiwan</term><term>Time Factors</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (effets indésirables)</term><term>Enfant</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Jeune adulte</term><term>Mâle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Résistance aux substances</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taïwan</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Taiwan</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Drug Resistance</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Facteurs de risque</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Indice de gravité médicale</term><term>Jeune adulte</term><term>Mâle</term><term>Résistance aux substances</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taïwan</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Taïwan</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the long-term safety and effectiveness of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Taiwan.</div></front></TEI><affiliations><list><country><li>Taïwan</li></country></list><tree><country name="Taïwan"><noRegion><name sortKey="Lin, Ching Tsai" sort="Lin, Ching Tsai" uniqKey="Lin C" first="Ching-Tsai" last="Lin">Ching-Tsai Lin</name></noRegion><name sortKey="Chen, Der Yuan" sort="Chen, Der Yuan" uniqKey="Chen D" first="Der-Yuan" last="Chen">Der-Yuan Chen</name><name sortKey="Chen, Yi Hsing" sort="Chen, Yi Hsing" uniqKey="Chen Y" first="Yi-Hsing" last="Chen">Yi-Hsing Chen</name><name sortKey="Chen, Yi Ming" sort="Chen, Yi Ming" uniqKey="Chen Y" first="Yi-Ming" last="Chen">Yi-Ming Chen</name><name sortKey="Hsieh, Chia Wei" sort="Hsieh, Chia Wei" uniqKey="Hsieh C" first="Chia-Wei" last="Hsieh">Chia-Wei Hsieh</name><name sortKey="Hsieh, Tsu Yi" sort="Hsieh, Tsu Yi" uniqKey="Hsieh T" first="Tsu-Yi" last="Hsieh">Tsu-Yi Hsieh</name><name sortKey="Huang, Wen Nan" sort="Huang, Wen Nan" uniqKey="Huang W" first="Wen-Nan" last="Huang">Wen-Nan Huang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000870 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000870 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28734675
|texte= Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28734675" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |